Biotech Co. Misled Investors About Role In Ebola Drug: Suit
A shareholder of plant-based pharmaceutical manufacturer iBio Inc. hit the company with a putative class action in Delaware federal court on Friday, alleging that iBio inflated its stock price by misleading...To view the full article, register now.
Already a subscriber? Click here to view full article